Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Disease overview
• Understanding the disease
PART 06: Pipeline analysis
PART 07: Market landscape
• Global multiple myeloma drugs market
• Five forces analysis
PART 08: Market segmentation by therapy
• Targeted therapy
• Biologic therapy
• Chemotherapy
• Others
PART 09: Geographical segmentation
• Multiple myeloma drugs market in Americas
• Multiple myeloma drugs market in EMEA
• Multiple myeloma drugs market in APAC
PART 10: Market drivers
• Growing demand for biologic therapies
• Paradigm shift toward the adoption of novel proteasome inhibitors
• Presence of large patient pool
PART 11: Impact of drivers
PART 12: Market challenges
• Growing popularity of complementary and alternative medicines (CAM)
• High costs affecting the adoption rates of multiple myeloma drugs
• Adverse effects of drugs
PART 13: Impact of drivers and challenges
PART 14: Market trends
• Emergence of nanomedicine platform
• Advent of microRNA therapeutics
• Increasing inorganic growth strategies
PART 15: Vendor landscape
• Competitive scenario
PART 16: Key vendor analysis
• Amgen
• Celgene
• Johnson & Johnson
• Novartis
• Takeda Pharmaceuticals
• Other prominent vendors
PART 17: Appendix
• List of abbreviations
PART 18: Explore Technavio
  List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key customer segments of global multiple myeloma drugs market
Exhibit 03: Factors affecting the adoption rates of multiple myeloma drugs market
Exhibit 04: Pipeline landscape
Exhibit 05: Pipeline analysis
Exhibit 06: Global multiple myeloma drugs market snapshot
Exhibit 07: Global multiple myeloma drugs market 2016-2021 ($ billions)
Exhibit 08: Opportunity analysis of global multiple myeloma drugs market
Exhibit 09: Opportunity analysis in developed and emerging markets

Exhibit 10: Five forces analysis
Exhibit 11: Segmentation of global multiple myeloma drugs market by therapy 2016
Exhibit 12: Lifecycle analysis of segments in global multiple myeloma drugs market 2016
Exhibit 13: Segmentation of global multiple myeloma drugs market based on geography 2016 and 2021
Exhibit 14: Multiple myeloma drugs market revenue by geography 2016-2021 ($ billions)
Exhibit 15: Market scenario in Americas
Exhibit 16: Multiple myeloma drugs market in Americas 2016-2021 ($ billions)
Exhibit 17: Market scenario in EMEA
Exhibit 18: Multiple myeloma drugs market in EMEA 2016-2021 ($ billions)
Exhibit 19: Market scenario in APAC
Exhibit 20: Multiple myeloma drugs market in APAC 2016-2021 ($ billions)
Exhibit 21: Key drivers and challenges in APAC
Exhibit 22: Impact of drivers
Exhibit 23: Alternative therapies for multiple myeloma drugs
Exhibit 24: Forcefield analysis of drivers and challenges
Exhibit 25: Impact of drivers and challenges
Exhibit 26: Key factors driving the adoption of nanomedicine
Exhibit 27: Factors driving the adoption of miRNA therapeutics
Exhibit 28: Key deals in global multiple myeloma drugs market
Exhibit 29: Competitive structure analysis of global multiple myeloma drugs market 2015
Exhibit 30: Market share analysis in global multiple myeloma drugs market
Exhibit 31: Competitive analysis of global multiple myeloma drugs market
Exhibit 32: Market penetration of various multiple myeloma drugs manufacturers worldwide (2016)
Exhibit 33: Amgen: Key highlights
Exhibit 34: Amgen: Strength assessment
Exhibit 35: Amgen: Strategy assessment
Exhibit 36: Amgen: Opportunity assessment
Exhibit 37: Celgene: Key highlights
Exhibit 38: Celgene: Strength assessment
Exhibit 39: Celgene: Strategy assessment
Exhibit 40: Celgene: Opportunity assessment
Exhibit 41: Celgene: YoY revenue and growth rate of REVLIMID 2013-2015 ($ billions)
Exhibit 42: Celgene: YoY revenue and growth rate of POMALYST 2013-2015 ($ millions)
Exhibit 43: Celgene: YoY revenue and growth rate of THALOMID 2013-2015 ($ millions)
Exhibit 44: Johnson & Johnson: Key highlights
Exhibit 45: Johnson & Johnson: Strength assessment
Exhibit 46: Johnson & Johnson: Strategy assessment
Exhibit 47: Johnson & Johnson: Opportunity assessment
Exhibit 48: Johnson & Johnson: YoY global revenue comparison of VELCADE 2013-2015 ($ billions)
Exhibit 49: Novartis: Key highlights
Exhibit 50: Novartis: Strength assessment
Exhibit 51: Novartis: Strategy assessment
Exhibit 52: Novartis: Opportunity assessment
Exhibit 53: Takeda Pharmaceuticals: Key highlights
Exhibit 54: Takeda Pharmaceuticals: Strength assessment
Exhibit 55: Takeda Pharmaceuticals: Strategy assessment
Exhibit 56: Takeda Pharmaceuticals: Opportunity assessment

Amgen, Celgene, Johnson & Johnson, Novartis, Takeda Pharmaceuticals, AB Science, AbbVie, Acceleron Pharma, Acetylon Pharmaceuticals, Adaptimmune Therapeutics, Alexion Pharmaceuticals, AmpliMed Corporation, Array BioPharma, Benovus Bio, BioInvent, Biokine Therapeutics, Biotest, bluebird bio, Bristol-Meyer Squibb, Calithera Biosciences, CASI Pharmaceuticals, Celldex Therapeutics, Cellectar Biosciences, Chroma Therapeutics, Cleave Biosciences, Curis, Dicerna Pharmaceuticals, Eureka Therapeutics, F. Hoffmann-La Roche, Geron Corporation, GlycoMimetics, GlaxoSmithKline, ImmunoGen, Immunomedics, Innate Pharma, JW Pharmaceutical, Karyopharm Therapeutics, Kyowa Hakko Kirin, Merck, Midatech Pharma, Mirna Therapeutics, Molecular Partners, MorphoSys, NOXXON Pharma, Oncoceutics, Oncolytics Biotech, OncoPep, Oncopeptides, Ono Pharmaceutical, Otsuka Pharmaceuticals, Patrys, PharmaMar, Polyphor, Prothena Therapeutics, Sanofi, Sevion Therapeutics, Specialised Therapeutics, Spectrum Pharmaceutical, SymBio Pharmaceuticals, TaiGen Biotechnology, Tragara Pharmaceuticals, Vaxil Therapeutics, and Vivolux.